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Abstract Current methods for pregnancy diagnostics are
based on immunodetection of pregnancy-specific proteins
and in a forensic context suffer from sensitivity and
specificity issues. Here, we applied reverse transcriptase
polymerase chain reaction (RT-PCR) technology to 11
genes previously reported with placental mRNA circulating
in maternal blood. We found two genes, hPL and βhCG,
with pregnancy-specific expression in whole blood samples.
RT-PCR detection of hPL was positive in all samples tested
throughout the pregnancy, whereas βhCG was detectable
until half of the second trimester but not at later gestation
ages. For hPL, in vitro stability of the transcript was
demonstrated until 2 months of age, and the hPL-specific
RT-PCR assay applied was highly sensitive with reliable
detection from down to 0.25 cm2 dried bloodstain. We
therefore suggest hPL-specific RT-PCR as a new molecular
tool for forensic pregnancy diagnostics from dried blood
stains. Moreover, our results indicate that the time-wise
reverse expression of hPL and βhCG during pregnancy
may allow an RT-PCR-based estimation of the gestational
age from blood stains, adding to the value of forensic
pregnancy diagnosis for crime scene investigations.
Keywords mRNAmarkers . Pregnancy .Maternal blood .
Forensic . hPL . βhCG
Introduction
The diagnosis of pregnancy from forensic bloodstains can be
useful in cases of infanticide, criminal abortions and for
missing person identification. However, this task is chal-
lenged by the usually small amounts of potentially degraded
biological material found at crime scenes that often is of
unknown age. Pregnancy diagnostics from bloodstains has
been demonstrated via immunodetection of pregnancy-
specific proteins [1], but the sensitivities achievable by this
approach [2] limit its application in a forensic context where
often minute dried bloodstains have to be investigated.
Consequently, there is a need for more sensitive techniques
to detect pregnancy-specific biomarkers from small blood-
stains found at crime scenes. Research in prenatal diagnos-
tics using reverse transcriptase polymerase chain reaction
(RT-PCR) has discovered the presence of various placenta-
derived mRNA species in maternal plasma [3–6] that are
reported to be remarkably stable in peripheral blood [7] and
are rapidly cleared from circulation post-partum [3]. Also,
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unlike previously employed immunodetection methods, RT-
PCR diagnostics can be designed to be human-specific
providing advantages in mixed human–animal samples
where protein-based assays may produce false positive
results. These characteristics make pregnancy-specific mRNA
markers analyzed by RT-PCR technology a logical choice for
the development of a pregnancy diagnostic test for forensic
applications. We, therefore, tested by means of RT-PCR
technology 11 genes previously reported with pregnancy-
specific expression [3–6] and evaluated, for those with
confirmed pregnancy-specific expression in whole blood
stains, the in vitro time-wise stability of the transcripts as
well as the RT-PCR sensitivity.
Materials and methods
Sample collection
To test for pregnancy-specific expression, we used blood
samples from healthy volunteers with singleton pregnancies
recruited from staff members of the Erasmus University
Medical Center Rotterdam and the Netherlands Forensic
Institute with informed consent. The samples were collected
with sterile cotton swabs after a finger prick and stored at
−80°C or in RNAlater solution (Applied Biosystems,
Nieuwerkerk aan de IJssel, the Netherlands) until RNA
isolation. The gestational age of these female volunteers
ranged from the 11.3th to the 37th week of pregnancy (the
digit behind the dot refers to extra days of the week
indicated before the dot). One swab or 200 μl of blood was
used for RNA isolation. Saliva samples were collected from
four pregnant volunteers in the 11.3th, 18th, 21st, and
37th weeks of gestation; two cotton swabs fully soaked
with fluid were used for RNA isolation. To determine the
relationship between gene expression and gestation time,
blood samples from women with singleton pregnancies
were provided by the Department of Obstetrics and
Gynecology of the Erasmus University Medical Center in
Rotterdam. These samples had been collected by venipunc-
ture during 2006 and 2007 in EDTA-containing tubes,
stored at −80°C and 200 μl of blood was used for RNA
isolation, which was performed in duplicate. The gestational
age of these female volunteers ranged from the 8.2th to the
20.1th week of pregnancy. In vitro time-wise stability of the
transcripts was tested on blood sampled obtained with
informed consent from three healthy volunteers who were
in the 11.1th, 27.5th, and 30.5th weeks of pregnancy,
respectively. For this, approximately 4 ml of blood was
drawn by venipuncture immediately processed to avoid
clotting: 2 ml of each blood sample was spread over a
56.7 cm2 piece of Whatman 3-MM filter paper placed in an
uncovered Petri dish. The rest of the sample was absorbed
with sterile cotton swabs. The filter paper and swabs were
stored at ambient temperature in dust-free non-humid
conditions and were subjected to normal daylight conditions.
RNA from these samples was isolated after different time
intervals; 1, 7, 14, 28, and 56 days. At each time point, RNA
was extracted from one blood swab, as well as 1.0, 0.5, 0.25,
0.1, 0.04, and 0.01 cm2 pieces of blood-soaked and dried
filter paper, which correspond to approximately 200.0, 35.3,
17.7, 8.8, 3.5, 1.4, and 0.4 μl of spotted blood, respectively.
RNA isolation, cDNA synthesis and quantitative RT-PCR
Total RNA isolation was performed with the RNeasy Plus
Mini kit (Qiagen Benelux B.V., Venlo, the Netherlands)
according to the manufacturer’s instructions with some
modifications. These included the incubation of the cotton
swabs and the pieces of filter paper in RLT buffer for 1 h at
4°C followed by acid phenol/chloroform extraction prior to
the loading of whole blood lysate onto the RNeasy spin
columns. This purification step significantly increased RNA
yield and purity (data not shown). RNA extracts were
treated with DNase using the Turbo DNA-free kit by
Ambion (Applied Biosystems) to remove genomic DNA
contamination. The quality and quantity of RNA was
assessed with a NanoDrop ND-1000 spectrophotometer
(Thermo Scientific, Wilmington, DE). For the RNA samples
designated for the pregnancy specificity determination,
cDNA synthesis was carried out with the Transcriptor First
Strand cDNA Synthesis kit (Roche Diagnostics Nederland
B.V., Almere, the Netherlands). RNA extracts designated for
the gestation time applicability and sensitivity studies were
reverse transcribed with the Revertaid H Minus First Strand
cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany)
with a combination of random hexamer and oligo(dT)18
primers. Real-time PCR reactions were performed in 15 μl
reaction volumes, in duplicate, on an ABI 7300 PCR
machine (Applied Biosystems). The PCR reactions for
GAPDH and β-actin genes used as endogenous controls
were performed with the FastStart Universal SYBR Green
master mix (Roche Diagnostics Nederland B.V., the
Netherlands) using previously described primer sequences
[8, 9] and the following cycling parameters during PCR:
initial denaturation at 95°C for 10 min, followed by
50 cycles of denaturation at 95°C for 15 s, and a final
annealing—elongation at 60°C for 60 s. The same SYBR
Green PCR kit was used for the testing of the pregnancy
specificity and the sensitivity of detection of the markers
described in Oudejans et al. [4] (LOC90625 and CSH1
genes) and Go et al. [5] (ZDHHC1, GCM1, PSG9, and
PAPPA genes) using the primers and specific PCR
conditions described in the original publications. RT-PCRs
with hydrolysis probes were performed using the Maxima
Probe qPCR Master Mix (Fermentas) with primer and
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probe sequences according to Ng et al. [3] for hPL and
βhCG genes and Tsui et al. [6] for TFPI2, Kiss1, and
PLAC1 genes. All primers used in the study were either
cDNA-specific or generated larger amplicons from genomic
DNA template allowing a clear differentiation between
products derived from mRNA and from genomic DNA.
Agarose gel electrophoresis was performed to confirm the
specificity of all amplifications.
Results and discussion
Pregnancy specificity of mRNA markers
Whole-blood RT-PCR analysis of 11 genes with previously
reported pregnancy-specific expression pattern (LOC90625,
CSH1, ZDHHC1, GCM1, PSG9, PAPPA, hPL, βhCG,
TFPI2, Kiss1, and PLAC1 [3–6]) performed in four samples
of different pregnant women as well as in four samples of
different non-pregnant female controls and in four male
control samples provided confirmation for two transcripts,
the human placental lactogen (hPL) and the beta subunit of
human chorionic gonadotropin (βhCG). The remaining nine
genes showed no pregnancy-specific expression pattern by
analyzing whole blood. HPL and βhCG were also tested in
samples of additional 4 different pregnant women; hPL was
detected in all eight samples from pregnant volunteers
(Fig. 1), while βhCG was detected in three of them. None
of the control samples from males and non-pregnant
females tested positive for any of the two transcripts. HPL
and βhCG RT-PCR was also performed on saliva samples
from four pregnant volunteers, and no amplification was
detected (data not shown). This finding confirms expect-
ations since hPL and βhCG expression is restricted to the
placenta [10] allowing mRNA amplification from maternal
blood but not from other body fluids of pregnant women
that usually contain no blood. The use of whole blood in
our study might serve as a possible explanation why the
nine genes that showed pregnancy-specific expression in
previous plasma-based studies [4–6] did not reveal preg-
nancy specificity in our study: cell components of whole
blood could contribute to the overall expression profile and
may have caused nonspecific amplification as observed
here.
Time window of hPL and βhCG mRNA detection
To investigate the time window of hPL and βhCG gene
expression throughout the pregnancy, we tested 25 additional
samples from women in their 8.2th to 20.1th gestation week
(Electronic Supplementary Material, Table S1). Together
with the eight samples mentioned in the previous section, we
detected hPL in all 33 samples tested from women in their
8.2th to 37th gestation weeks, whereas βhCG mRNA was
successfully amplified from 24 of the 33 samples tested.
Notably, βhCG mRNA was not detected beyond the 20.1th
week of pregnancy in the samples tested. These 25 samples
were also used for reproducibility testing; for hPL, positive
results were obtained for all technical replicates (100%
reproducibility), whereas the technical reproducibility of the
βhCG RT-PCR assay was 100% only with samples from
women until the 10.1th week of pregnancy but decreased in
samples from women of later gestational age (Electronic
Supplementary Material, Table S1). These results are in line
with previous reports [3, 10] showing that the concentration
throughout the pregnancy of hPL mRNA in maternal blood
is higher relative to βhCG and that the level of βhCG
mRNA decreases significantly after early pregnancy down to
a few copies per milliliter of blood at late gestation age. The
mRNA of both endogenous controls used (GAPDH and β-
actin) was detected in all 33 samples of pregnant volunteers
as well as in samples from males and from non-pregnant
females without major quantitative differences (see Fig. 1 for
GAPDH) demonstrating successful cDNA synthesis from the
total RNA extracts and confirming previous reports of
pregnancy-independent expression [3, 11]. Given that the
amount of hPL mRNA in maternal blood increases as the
pregnancy progresses [3, 10], one can conclude that hPL
mRNA will be detectable at older gestation age than the
37th week available to us and until full term. The earliest
point in the gestation period allowing the detection of hPL
and βhCG mRNA is expected to be before the 8.2th week
available to us; according to Okazaki et al. [10], both
transcripts are detectable in samples from women of the sixth
week of gestation.
Sensitivity of hPL and βhCG mRNA assays
Because the concentrations of hPL mRNA increases with
gestation time reaching the peak at the third trimester [3,
Fig. 1 Agarose gel electrophoresis with ethidium bromide staining of
RT-PCR reactions with RNA from whole blood of eight different
pregnant women in their 13th until 37th week of pregnancy (lanes 1–8)
and four different non-pregnant women (lanes 9–12). a hPL mRNA
amplifications (expected product size: 97 bp). b GAPDH mRNA
amplifications (expected product size: 260 bp). Lane M corresponds to
a 50-base pair molecular size ladder and lane 13 corresponds to no
template control reactions
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10], we chose samples from the latest gestation period for
which sufficient material was available to us (two donors in
the 27.5th and the 30.5th week of gestation) to determine
the smallest amount of dried blood required for reliable RT-
PCR detection of hPL mRNA. We revealed that hPL
amplification is possible from as little as 0.25 cm2 dried
bloodstain (corresponding to 8.8 μl of liquid blood or
∼50 ng total RNA). This approximately corresponds to the
smallest reported amount from which the hPL protein was
detected previously by immunodetection [1]. Since the
amount of βhCG mRNA is maximal at the first trimester [3,
10], we used a sample from the earliest gestation period for
which sufficient material was available to us (11.1th week)
to determine the RT-PCR sensitivity limits for βhCG
mRNA detection. We found that reproducible βhCG
amplification could not be achieved by using less material
than one standard blood-soaked dried cotton swab
corresponding to about 200 μl of liquid blood (or 200–
1,000 ng total RNA as extracted from dried blood). This is
in line with 100% reproducibility of βhCG-specific RT-
PCR in samples from women in their 8.2th-10.1th week
obtained from 200 μl of liquid blood (or 500–2,000 ng total
RNA; Electronic Supplementary Material, Table S1).
However, we are aware that the gestation period of the
sample available to us for this experiment does not
correspond to the period of maximal βhCG expression [3,
10]. The relatively high detection limit for βhCG using the
RT-PCR assay applied and the fact that the βhCG transcript
is not detectable throughout the entire gestational age limits
the use of βhCG mRNA to detect pregnancy from forensic
blood stains (but see last chapter).
Time-wise stability of hPL mRNA
The Ct values for GAPDH, β-actin, and hPL PCR
amplifications of the RNA extracted from the bloodstains
obtained from women in the 27.5th and 30.5th weeks of
pregnancy did not demonstrate any regular trend of change
depending on the time of sample storage from 1 to 56 days,
although increased variation of Ct values in the dried
samples in comparison to the fresh ones was observed, as
might be expected (data not shown). However, we were
able to successfully detect hPL mRNA in dried bloodstains
after at least 56 days of stain exposure at room temperature.
Although mRNA is generally believed to be highly
unstable and prone to degradation due to the action of
ribonucleases and environmental factors such as pH, UV
light, and moisture [12], it has been shown recently that
some RNA markers might be exceptionally stable [13, 14].
Therefore, our results of about 2 months in vitro stability
indicate that sample degradation is not a strongly limiting
factor for forensic pregnancy diagnostics, at least when
using hPL mRNA as marker and considering the environ-
mental conditions applied.
Relationship between hPL and βhCG expression
with gestation time
Initiated by the observed differences in the expression
pattern between hPL and βhCG in samples of different
gestation age, we were interested in studying the relation-
ship between both transcripts throughout the pregnancy
period in more detail. Using the RT-PCR data obtained
Fig. 2 Scatter plot of the average
threshold cycle (Ct) value differ-
ences between βhCG and hPL
mRNA amplifications of a given
sample in relation to the gesta-
tional age of the sample donor.
Only the samples with more than
50% of positive amplifications
across all technical replicates
were used to calculate the mean
Ct and produce the scatter plot
(see Electronic Supplementary
Material, Table S1 for details)
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from the hPL and βhCG assays in samples from women in
their 8.2th to 20.1th gestation week (Electronic Supple-
mentary Material, Table S1), a statistically significant
positive correlation (R2=0.6445, p<0.001) was observed
between the threshold cycle (Ct) value differences of
βhCG and hPL and the gestational age of the sample
donor (Fig. 2). Even though βhCG mRNA cannot be
detected throughout the entire period of a normal
pregnancy, our data indicate that when combined with
the detection of hPL mRNA, it may become useful in
predicting gestational age from a forensic bloodstain that
originated from a pregnant woman. However, the success
of such additional application will depend on future
improvements of the βhCG RT-PCR assay, which may be
achievable by further optimizing the three main steps of
the RT-PCR approach: RNA extraction, cDNA synthesis,
and PCR amplification and using samples from the
complete pregnancy period.
Conclusions
Our data demonstrate that RT-PCR allows the detection of
pregnancy-specific hPL and βhCG mRNA transcripts
from small blood stains. The hPL-specific RT-PCR assay
applied was sensitive enough to reliably detect hPL
transcripts throughout the pregnancy, and from as little
as 0.25 cm2 of dried bloodstain. Furthermore, the hPL
transcript was shown to be stable enough for successful
amplification from dried blood of up to 2 months of age,
expectedly older. Therefore, we propose hPL-specific RT-
PCR as new molecular tool for pregnancy diagnostics
from blood stains found at crime scenes. Moreover, our
results indicate that a combined analysis of hPL and βhCG
mRNA markers may allow estimating the gestational age
of a woman from her blood stain left behind, potentially
adding to the value of forensic pregnancy diagnosis for
crime scene investigations.
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